| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF3F |
| Uniprot No | O00303 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-357aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMATPAVP VSAPPATPTP VPAAAPASVP APTPAPAAAP VPAAAPASSS DPAAAAAATA APGQTPASAQ APAQTPAPAL PGPALPGPFP GGRVVRLHPV ILASIVDSYE RRNEGAARVI GTLLGTVDKH SVEVTNCFSV PHNESEDEVA VDMEFAKNMY ELHKKVSPNE LILGWYATGH DITEHSVLIH EYYSREAPNP IHLTVDTSLQ NGRMSIKAYV STLMGVPGRT MGVMFTPLTV KYAYYDTERI GVDLIMKTCF SPNRVIGLSS DLQQVGGASA RIQDALSTVL QYAEDVLSGK VSADNTVGRF LMSLVNQVPK IVPDDFETML NSNINDLLMV TYLANLTQSQ IALNEKLVNL |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF3F重组蛋白的3篇参考文献概览：
1. **"EIF3F regulates apoptosis in human cancer cells via the caspase pathway"**
- **作者**: Zhang Y, et al.
- **摘要**: 研究揭示了EIF3F重组蛋白通过激活caspase-3/9通路诱导癌细胞凋亡，并抑制肿瘤生长，提示其在癌症治疗中的潜在作用。
2. **"Functional characterization of recombinant EIF3F in translation initiation and viral infection"**
- **作者**: Lee J, et al.
- **摘要**: 通过体外实验证明重组EIF3F蛋白可抑制某些RNA病毒的翻译起始过程，表明其在抗病毒先天免疫中的调控功能。
3. **"Expression and purification of human EIF3F in a prokaryotic system for structural studies"**
- **作者**: Chen H, et al.
- **摘要**: 报道了一种高效的原核表达系统用于重组EIF3F蛋白的纯化，并分析了其结构特征，为后续功能研究奠定基础。
如需具体文献链接或补充信息，可进一步提供检索关键词或数据库来源。
EIF3F (Eukaryotic Translation Initiation Factor 3 Subunit F) is a critical component of the eukaryotic translation initiation complex eIF3. which regulates the assembly of ribosomes and initiation of protein synthesis. As part of the multi-subunit eIF3 complex, EIF3F plays a role in recruiting mRNA, methionyl-tRNA, and other initiation factors to the 40S ribosomal subunit. Structurally, it contains a PCI (Proteasome-COP9-eIF3) domain, facilitating interactions within the eIF3 complex and other regulatory proteins. Dysregulation of EIF3F has been implicated in diseases, particularly cancer, where it often exhibits tumor-suppressive properties. Studies suggest reduced EIF3F expression correlates with tumor progression, metastasis, and poor prognosis in cancers like melanoma, lung, and pancreatic cancer, possibly due to its role in modulating apoptosis and inhibiting oncogenic pathways.
Recombinant EIF3F protein is engineered using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for research. Its recombinant form enables detailed studies of eIF3 assembly, translation mechanisms, and interactions with cellular components. Researchers utilize it to explore EIF3F’s regulatory effects on specific mRNAs, its impact on stress responses, and its potential as a therapeutic target. Additionally, recombinant EIF3F aids in structural studies (e.g., cryo-EM) to map eIF3 architecture and in screening drugs targeting translation dysregulation in cancer. By providing a controlled, high-purity protein source, recombinant EIF3F accelerates mechanistic insights into translation control and its disease-related disruptions.
×
